Postinflammatory hyperpigmentation: A comprehensive overview : Epidemiology, pathogenesis, clinical presentation, and noninvasive assessment technique - 14/09/17
Abstract |
Postinflammatory hyperpigmentation (PIH) commonly occurs after various endogenous and exogenous stimuli, especially in dark-skinned individuals. PIH is one of the most common complications of procedures performed using laser and other light sources. The severity of PIH is determined by the inherent skin color, degree and depth of inflammation, degree of dermoepidermal junction disruption, inflammatory conditions, and the stability of melanocytes, leading to epidermal and dermal melanin pigment deposition. The depth of melanin pigment is the key factor to predict prognosis and treatment outcome. Epidermal hyperpigmentation fades more rapidly than dermal hyperpigmentation. Various inflammatory disorders can eventually result in PIH. The evaluation of pigmentation using noninvasive tools helps define the level of pigmentation in the skin, pigmentation intensity, and guides therapeutic approaches. This first article in this 2-part series discusses the epidemiology, pathogenesis, etiology, clinical presentation, differential diagnoses, and investigation using noninvasive assessment techniques that objectively determine the details of pigmentation.
Le texte complet de cet article est disponible en PDF.Key words : colorimetry, hyperpigmentation, hyperspectral imaging, melanin, melanocytes, photography, racial/ethnic, reflectance confocal microscopy, reflectance spectroscopy, skin phototypes
Abbreviations used : DRS, HSI, PAHPI, PIH, SOC, SPT, UV
Plan
Funding sources: None. |
|
Dr Kohli is a subinvestigator for Ferndale Laboratories, Estee Lauder, Johnson & Johnson, and Allergan, and is a consultant for Pfizer. Dr Hamzavi is an investigator for Clinuvel, Estee Lauder, Allergan, Ferndale Laboratories, and Johnson & Johnson, and is a consultant for Aclaris Therapeutics. Dr Lim has served as a consultant for Pierre Fabre and is an investigator for Clinuvel, Estee Lauder, and Ferndale Laboratories. Drs Silpa-archa and Chaowattanapanit have no conflicts of interest to declare. |
|
Date of release: October 2017 |
|
Expiration date: October 2020 |
Vol 77 - N° 4
P. 591-605 - octobre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?